Organic anion-transporting polypeptides: A novel approach for cancer therapy

Journal of Drug Targeting

Volumn 22, Issue 1, 2014, Pages 14-22

  Liu, Tianyu ^a   Li, Qingyong ^a,b  

^a NORTHEAST FORESTRY UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Clinical drugs; Drug design; Genetic polymorphisms; Transporter

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ATRASENTAN; BILE ACID; BIOLOGICAL MARKER; BOSENTAN; BROMSULFOPHTHALEIN; CASPOFUNGIN; CEPHALOSPORIN; ENALAPRIL; FEXOFENADINE; FLAVOPIRIDOL; GADOLINIUM; MYCOPHENOLIC ACID; OLMESARTAN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PENICILLIN G; PROSTAGLANDIN; PROTEINASE INHIBITOR; RAPAMYCIN; RIFAMPICIN; STEROID HORMONE; TELMISARTAN; TEMOCAPRIL; TESTOSTERONE; THYROID HORMONE; TORASEMIDE; VALSARTAN;

CANCER THERAPY; DRUG DESIGN; ENZYME SUBSTRATE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; ORGANIC ANION TRANSPORTERS; TUMOR MARKERS, BIOLOGICAL;

EID: 84890352958     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.832767     Document Type: Review

References (62)

1. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 2012;52:135-51.
2. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011;63: 157-81.
3. Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic diposition of drugs. Drug Metab Pharmacokinet 2012;27:106-21.
4. König J, Cui Y, Nies AT, et al. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000;278: G156-64.
5. Sainis I, Fokas D, Vareli K, et al. Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs. Mar Drugs 2010;8: 629-57.
6. Pressler H, Sissung TM, Venzon D, et al. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 2011;6:e20372. doi: 10.1371/journal.pone.0020372.
7. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158:693-705.
8. Ulvestad M, Björquist P, Molden E, et al. OATP1B1/1B3 activity in plated primary human hepatocytes over time in culture. Biochem Pharmacol 2011;82:1219-26.
9. Hilgendorf C, Ahlin G, Seithel A, et al. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos 2007;35:1333-40.
10. König J, Cui Y, Nies AT, et al. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000b;275:23161-8.
11. De Bruyn T, Ye ZW, Peeters A, et al. Determination of OATP-, NTCP-and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. Eur J Pharm Sci 2011;43:297-307.
12. Cui Y, König J, Leier I, et al. Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J Biol Chem 2001;276:9626-30.
13. Campbell SD, de Morais SM, Xu JJ. Inhibition of human organic anion transporting polypeptide OATP1B1 as a mechanism of druginduced hyperbilirubinemia. Chem Biol Interact 2004;150:179-87.
14. Hagenbuch B, Gui C. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 2008; 38:778-801.
15. Oostendorp RL, van de Steeg E, van der Kruijssen CM, et al. Organic anion-transporting polypeptide 1B1 mediates transport of gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos 2009;37:917-23.
16. Feng B, Xu JJ, Bi YA, et al. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714. Toxicol Sci 2009;108:492-500.
17. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-8.
18. Nozawa T, Minami H, Sugiura S, et al. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of Irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005;33:434-9.
19. Herraez E, Macias RI, Vazquez-Tato J, et al. In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicol Appl Pharmacol 2009;239:13-20.
20. Fischer A, Hoeger SJ, Stemmer K, et al. The role of organic anion transporting polypeptides (OATPs/SLCOs) in the toxicity of different microcystin congeners in vitro: a comparison of primary human hepatocytes and OATP-transfected HEK293 cells. Toxicol Appl Pharmacol 2010;245:9-20.
21. Gui C, Obaidat A, Chaguturu R, et al. Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics 2010;4:1-8.
22. Yamaguchi H, Okada M, Akitaya S, et al. Transport of fluorescent chenodeoxycholic acid via the human organic anion transporters OATP1B1 and OATP1B3. J Lipid Res 2006;47:1196-202.
23. Bednarczyk D. Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3. Anal Biochem 2010;405:50-8.
24. Tirona RG, Leake BF, Merino G, et al. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European-and African-Americans. J Biol Chem 2001;276:35669-75.
25. Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 2008;9:19-33.
26. Ghatak A, Faheem O, Thompson PD. The genetics of statininduced myopathy. Atherosclerosis 2010;210:337-43.
27. Letschert K, Keppler D, König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14: 441-52.
28. Schwarz UI, Meyerzu Schwabedissen HE, Tirona RG, et al. Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrates specificity. Pharmacogenet Genomics 2011;21:103-14.
29. Eckhardt U, Horz JA, Petzinger E, et al. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic aniontransporting polypeptide. Hepatology 1996;24: 380-4.
30. Buxhofer-Ausch V, Secky L, Wlcek K, et al. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv 2013. [Epub ahead of print]. doi:10.1155/2013/ 863539.
31. Arakawa H, Nakanishi T, Yanagihara C, et al. Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions. Biochem Pharmacol 2012;84:1070-7.
32. Cheng Z, Liu H, Yu N, et al. Hydrophilic anti-migraine triptans are substrates for OATP1A2, a transporter expressed at human bloodbrain barrier. Xenobiotica 2012;42:880-90.
33. Yamakawa Y, Hamada A, Shuto T, et al. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther 2011;90: 157-63.
34. Franke RM, Scherkenbach LA, Sparreboom A. Pharmacogenetics of the organic anion transporting polypeptide 1A2. Pharmacogenomics 2009;10:339-44.
35. Iida A, Saito S, Sekine A, et al. Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides,and three NADH: ubiquinone oxidoreductase flavoproteins. J Hum Genet 2001;46:668-83.
36. Badagnani I, Castro RA, Taylor TR, et al. Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther 2006;318:521-9.
37. Eechoute K, Franke RM, Loos WJ, et al. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 2011;89:816-20.
38. Kato K, Shirasaka Y, Kuraoka E, et al. Intestinal absorption mechanism of tebipenem pivoxil, a novel oral carbapenem: involvement of human OATP family in apical membrane transport. Mol Pharm 2010;7:1747-56.
39. Stute P, Reichenbach A, Szuwart T, et al. Impact of testosterone on the expression of organic anion transporting polypeptides (OATP-1A2, OATP-2B1, OATP-3A1) in malignant and non-malignant human breast cells in vitro. Maturitas 2012;71:376-84.
40. Meyerzu Schwabedissen HE, Tirona RG, Yip CS, et al. Interplay between the nuclear receptor PXR and the uptake transporter OATP1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 2008;68:9338-47.
41. Eloranta JJ, Hiller C, Jüttner M, Kullak-Ublick GA. The SLCO1A2 gene, encoding human organic anion-transporting polypeptide 1A2, is transactivated by the vitamin D receptor. Mol Pharm 2012;82: 37-46.
42. Zhou F, Lee AC, Krafczyk K, et al. Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 2011;162:1380-8.
43. Tamai I, Nezu J, Uchino H, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273:251-60.
44. Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev 2012;64:508-14.
45. Ho R, Leake BF, Kim RB, et al. OATP2B1 allelic variants differentially transport rosuvastatin in vitro. Drug Metab Rev 2006; 38:240-1.
46. Imanaga J, Kotegawa T, Imai H, et al. The effects of the SLCO2B1 c.1457CNT polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet Genomics 2011;21:84-93.
47. Ieiri I, Doi Y, Maeda K, et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 2012;52:1078-89.
48. Mougey EB, Feng H, Castro M, et al. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 2009;19:129-38.
49. Wright JL, Kwon EM, Ostrander EA, et al. Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SCLO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomark Prev 2011;4:619-27.
50. Nozawa T, Suzuki M, Takahashi K, et al. Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther 2004;311:1032-7.
51. Pizzagalli F, Hagenbuch B, Stieger B, et al. Identification of a novel human organic anion transporting polypeptide (OATP-F) as a high affinity thyroxine transporter. Mol Endocrinol 2002;16:2283-96.
52. Liedauer R, Svoboda M, Wlcek K, et al. Different expression patterns of organic anion transporting polypeptides in osteosarcomas, bone metastases and aneurysmal bone cysts. Oncol Rep 2009;22:1485-92.
53. Mandery K, Bujok K, Schmidt I, et al. Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa. J Pharmacol Exp Ther 2010;332:345-51.
54. Huber RD, Gao B, Sidler Pfändler MA, et al. Characterization of two splice variants of human organic anion transporting polypeptide 3A1 isolated from human brain. Am J Physiol Cell Physiol 2007;292:C795-806.
55. Sato K, Sugawara J, Sato T, et al. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta 2003;24:144-8.
56. Suzuki T, Toyohara T, Akiyama Y, et al. Transcriptional regulation of organic anion transporting polypeptide SLCO4C1 as a new therapeutic modality to prevent chronic kidney disease. J Pharm Sci 2011;100:3696-707.
57. Mikkaichi T, Suzuki T, Onogawa T, et al. Isolation and characterization of a digoxin transporter and its rat homologue expressed in the kidney. Proc Natl Acad Sci USA 2004;101:3569-74.
58. Chu XY, Bleasby K, Yabut J, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther 2007;321:673-83.
59. Kindla J, Rau TT, Jung R, et al. Expression and localization of the uptake transporters OATP2B1, OATP3A1 and OATP5A1 in nonmalignant and malignant breast tissue. Cancer Biol Ther 2011;11: 584-91.
60. Kullak-Ublick GA, Ismair MG, Stieger B, et al. Organic aniontransporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-33.
61. Hartkoorn RC, Kwan WS, Shallcross V, et al. HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet Genomics 2010;20:112-20.
62. Takada T, Weiss HM, Kretz O, et al. Hepatic transport of PKI166, an epidermal growth factor receptor kinase inhibitor of the pyrrolopyrimidine class, and its main metabolite, ACU154. Drug Metab Dispos 2004;32:1272-78.